End-of-day quote
Shanghai S.E.
18:00:00 2024-06-20 EDT
|
5-day change
|
1st Jan Change
|
76.9
CNY
|
+5.63%
|
|
+25.24%
|
+71.08%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
8,811
|
4,890
|
9,583
|
16,394
|
-
|
-
|
Enterprise Value (EV)
1 |
8,811
|
4,890
|
9,583
|
16,394
|
16,394
|
16,394
|
P/E ratio
|
68.9
x
|
37.6
x
|
59.1
x
|
60.2
x
|
41.5
x
|
30
x
|
Yield
|
-
|
-
|
0.89%
|
0.79%
|
1.23%
|
1.69%
|
Capitalization / Revenue
|
13.7
x
|
7.51
x
|
9.25
x
|
10.9
x
|
7.84
x
|
5.83
x
|
EV / Revenue
|
13.7
x
|
7.51
x
|
9.25
x
|
10.9
x
|
7.84
x
|
5.83
x
|
EV / EBITDA
|
41.1
x
|
21.4
x
|
29.4
x
|
33.5
x
|
24.2
x
|
18.2
x
|
EV / FCF
|
-
|
-
|
-
|
-34.3
x
|
-45.3
x
|
49.8
x
|
FCF Yield
|
-
|
-
|
-
|
-2.92%
|
-2.21%
|
2.01%
|
Price to Book
|
4.86
x
|
2.56
x
|
4.37
x
|
6.99
x
|
6.2
x
|
5.37
x
|
Nbr of stocks (in thousands)
|
213,184
|
213,184
|
213,184
|
213,184
|
-
|
-
|
Reference price
2 |
41.33
|
22.94
|
44.95
|
76.90
|
76.90
|
76.90
|
Announcement Date
|
22-02-27
|
23-02-27
|
24-02-23
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
643.9
|
651.3
|
1,036
|
1,509
|
2,091
|
2,811
|
EBITDA
1 |
-
|
214.2
|
228.3
|
325.4
|
489.7
|
678.3
|
901
|
EBIT
1 |
-
|
128.3
|
124.9
|
189.1
|
309.8
|
453.8
|
631
|
Operating Margin
|
-
|
19.93%
|
19.17%
|
18.26%
|
20.53%
|
21.7%
|
22.45%
|
Earnings before Tax (EBT)
1 |
-
|
125.7
|
123.2
|
170
|
311.3
|
454.3
|
634
|
Net income
1 |
123.4
|
115.4
|
129.1
|
161.3
|
271.5
|
394.2
|
545.8
|
Net margin
|
-
|
17.92%
|
19.82%
|
15.58%
|
18%
|
18.85%
|
19.41%
|
EPS
2 |
0.7700
|
0.6000
|
0.6100
|
0.7600
|
1.278
|
1.855
|
2.562
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-478
|
-362
|
329
|
FCF margin
|
-
|
-
|
-
|
-
|
-31.68%
|
-17.31%
|
11.7%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
36.51%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
60.28%
|
Dividend per Share
2 |
-
|
-
|
-
|
0.4000
|
0.6050
|
0.9450
|
1.300
|
Announcement Date
|
21-04-25
|
22-02-27
|
23-02-27
|
24-02-23
|
-
|
-
|
-
|
Fiscal Period: December |
2023 Q2
|
2023 Q3
|
---|
Net sales
|
-
|
-
|
EBITDA
|
-
|
-
|
EBIT
|
-
|
-
|
Operating Margin
|
-
|
-
|
Earnings before Tax (EBT)
|
-
|
-
|
Net income
1 |
20.84
|
49.86
|
Net margin
|
-
|
-
|
EPS
|
0.1000
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
23-08-28
|
23-10-20
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-
|
-
|
-478
|
-362
|
329
|
ROE (net income / shareholders' equity)
|
-
|
7.97%
|
6.94%
|
8.18%
|
11.5%
|
14.8%
|
17.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
5.29%
|
7.89%
|
10.2%
|
12.4%
|
Assets
1 |
-
|
-
|
-
|
3,050
|
3,441
|
3,863
|
4,414
|
Book Value Per Share
2 |
-
|
8.500
|
8.960
|
10.30
|
11.00
|
12.40
|
14.30
|
Cash Flow per Share
2 |
-
|
0.8500
|
0.1400
|
1.640
|
1.810
|
1.510
|
1.940
|
Capex
1 |
-
|
233
|
438
|
659
|
391
|
377
|
227
|
Capex / Sales
|
-
|
36.19%
|
67.3%
|
63.64%
|
25.92%
|
18.04%
|
8.08%
|
Announcement Date
|
21-04-25
|
22-02-27
|
23-02-27
|
24-02-23
|
-
|
-
|
-
|
Last Close Price
76.9
CNY Average target price
62.24
CNY Spread / Average Target -19.06% Consensus |
1st Jan change
|
Capi.
|
---|
| +71.08% | 2.26B | | +51.63% | 796B | | +41.51% | 628B | | -5.10% | 358B | | +19.90% | 331B | | +9.95% | 301B | | +17.66% | 244B | | +3.39% | 228B | | +10.75% | 214B | | +6.99% | 165B |
Other Pharmaceuticals
|